Atlas Venture Life Science Advisors’s Kymera Therapeutics KYMR Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$381M	Sell	4,578,008 -81,866	-2%	-$6.48M	48.26%	1
2025 Q4	$363M	Sell	4,659,874 -236,588	-5%	-$16M	41.91%	1
2025 Q3	$277M	Hold	4,896,462	–	–	36.82%	1
2025 Q2	$214M	Hold	4,896,462	–	–	32.26%	1
2025 Q1	$134M	Hold	4,896,462	–	–	25.69%	1
2024 Q4	$197M	Hold	4,896,462	–	–	24.03%	1
2024 Q3	$232M	Sell	4,896,462 -453,960	-8%	-$20M	21.48%	2
2024 Q2	$160M	Sell	5,350,422 -26,940	-0.5%	-$933K	16.82%	2
2024 Q1	$216M	Sell	5,377,362 -480,900	-8%	-$17.2M	19.95%	2
2023 Q4	$149M	Hold	5,858,262	–	–	17.76%	1
2023 Q3	$81.4M	Hold	5,858,262	–	–	12.61%	4
2023 Q2	$135M	Hold	5,858,262	–	–	16.76%	2
2023 Q1	$174M	Sell	5,858,262 -126,474	-2%	-$4.08M	23.5%	1
2022 Q4	$149M	Sell	5,984,736 -890,962	-13%	-$23.8M	17.99%	2
2022 Q3	$150M	Hold	6,875,698	–	–	16.52%	3
2022 Q2	$135M	Hold	6,875,698	–	–	22.63%	2
2022 Q1	$291M	Hold	6,875,698	–	–	36.79%	1
2021 Q4	$437M	Buy	+6,875,698	New	+$400M	40.09%	1

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Atlas Venture Life Science Advisors's KYMR Position: Q1 2026 in Review

Atlas Venture Life Science Advisors reduced its Kymera Therapeutics (KYMR) stake by 1.8% in Q1 2026, selling an estimated $6.48M and leaving 4,578,008 shares worth $381M. The position accounts for 48.26% of the portfolio, ranked #1.

Atlas Venture Life Science Advisors first reported a position in KYMR in Q4 2021 and has held it in 18 quarters since. The position peaked at $437M in Q4 2021. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

Atlas Venture Life Science Advisors held 4,578,008 shares of Kymera Therapeutics worth $381M as of Q1 2026.
Atlas Venture Life Science Advisors sold 81,866 Kymera Therapeutics shares in Q1 2026, an estimated $6.48M.
Kymera Therapeutics made up 48.26% of Atlas Venture Life Science Advisors's portfolio in Q1 2026, its #1 holding.
Atlas Venture Life Science Advisors first reported a position in Kymera Therapeutics in Q4 2021 and has held it in 18 quarters since.
Atlas Venture Life Science Advisors's Kymera Therapeutics position peaked at $437M in Q4 2021.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2026, filed 14 May 2026.